(Q35168051)

6 August 2017

1 reference

title

Outcome studies in diabetic nephropathy (English)

1 reference

6 August 2017

Anupama Mohanram

1

1 reference

6 August 2017

Robert D Toto

series ordinal

2

1 reference

6 August 2017

publication date

1 May 2003

1 reference

6 August 2017

published in

Seminars in Nephrology

1 reference

6 August 2017

volume

23

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

255-271

1 reference

Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Diabetic nephropathy: prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Excess incidence of treatment of end-stage renal disease in Mexican Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Determinants of end-stage renal disease in Pima Indians with Type 2 (non-insulin-dependent) diabetes mellitus and proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Diabetic kidney disease in Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Pathogenesis of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Activation of protein kinase c-delta and c-epsilon by oxidative stress in early diabetic rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Glucose-induced insulin resistance of phosphatidylinositol 3'-OH kinase and AKT/PKB is mediated by the hexosamine biosynthesis pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Diabetic nephropathy and arterial hypertension. The effect of antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The effect of strict short-term metabolic control on retinal nervous system abnormalities in newly diagnosed Type 1 (insulin-dependent) diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Preventing diabetic nephropathy: an audit

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Hypertension and diabetes: the scope of the problem

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Prevention of diabetic renal disease with special reference to microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Standards of medical care for patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Angiotensin II and its receptors in the diabetic kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Glomerular hemodynamics in experimental diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Diabetic nephropathy. Metabolic versus hemodynamic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Reversing glomerular hypertension stabilizes established glomerular injury

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Is angiotensin II's role in fibrosis as easy as PAI(-1)?

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Current concepts in glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effects of eprosartan on glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The role of proteinuria in the progression of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Remission of nephrotic-range albuminuria in type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Cigarette Smoking and Progression of Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Smoking is associated with progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Renal hemodynamic changes during smoking: effects of adrenoreceptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Anaemia management in chronic kidney disease patients: an overview of current clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Renal protective effect of enalapril in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Angiotensin II subtype 1 receptor blockers and renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Differential regulation of angiotensin peptide levels in plasma and kidney of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Antihypertensive Therapy with MK 4211

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Local angiotensin II-generating system in vascular tissues: the roles of chymase

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Aldosterone in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Evolution of incipient nephropathy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Plasma aldosterone concentrations in chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Nocturnal blood pressure and relation to vasoactive hormones and renal function in hypertension and chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Ambulatory blood pressure monitoring is a useful clinical tool in nephrology.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Left ventricular mass assessed by electrocardiography and albumin excretion rate as a continuum in untreated essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Circadian variation of blood pressure in patients with chronic renal failure on continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0270-9295%2803%2900061-5

7 January 2021

10.1016/S0270-9295(03)00061-5

Identifiers

DOI

1 reference

6 August 2017

1 reference